ge
gen
decoct
ggd
tradit
chines
medicin
prescript
mainli
use
treat
infecti
respiratori
diseas
reliev
symptom
influenza
viru
iav
infect
howev
underli
mechan
ggd
iav
infect
remain
unclear
studi
found
ggd
moder
antiiav
activ
vitro
ggd
effect
given
viral
infect
target
viral
attach
replic
stage
rather
intern
stage
vivo
ggd
treatment
reduc
viru
titer
lung
tissu
significantli
improv
surviv
rate
lung
index
pulmonari
histopatholog
chang
mice
observ
chang
sever
key
immunorel
index
ggd
administr
mice
antiiav
drug
oseltamivir
phosphat
control
ggd
treatment
decreas
express
improv
immun
balanc
reduc
excess
immun
respons
mice
besid
express
tolllik
receptor
signal
pathway
mice
decreas
ggd
treatment
result
show
ggd
antiiav
activ
modul
immun
system
reliev
lung
inflamm
influenza
infecti
diseas
pose
huge
threat
human
health
current
vaccin
antivir
medicin
effect
therapi
influenza
howev
iav
readili
mutat
allow
drugresist
mutant
emerg
thu
vital
develop
addit
therapeut
strategi
tackl
drug
resist
awar
intrigu
bioactiv
mani
chines
herbal
extract
grown
much
research
focus
tcm
tcm
made
import
contribut
treatment
acut
infecti
diseas
sar
tcm
use
extract
contain
mani
bioactiv
ingredi
antivir
mechan
tcm
differ
common
antivir
drug
contain
singl
chemic
usual
target
pathway
vital
viru
growth
thu
understand
uniqu
mode
action
tcm
influenza
infect
may
bring
new
insight
fight
viral
infect
ge
gen
decoct
ggd
kakkonto
japanes
tradit
medicin
galgeuntang
korean
tradit
medicin
tcm
prescript
origin
treatis
febril
diseas
prescript
consist
pueraria
lobata
ephedra
sinica
cinnamomum
cassia
glycyrrhiza
uralensi
paeonia
lactiflora
zingib
officinal
ziziphu
jujuba
ggd
mainli
use
treat
common
cold
influenza
infect
allevi
upper
back
pain
use
wide
clinic
practic
china
japan
report
advers
reaction
sever
studi
found
treatment
ggd
reliev
influenzalik
symptom
although
ggd
cur
effect
influenza
infect
underli
mechan
unclear
ggd
allevi
pulmonari
inflamm
reduc
mortal
iavinfect
mice
howev
effect
viru
titer
lung
tissu
bronchoalveolar
lavag
fluid
balf
seen
contrast
anoth
studi
indic
ggd
significantli
reduc
viru
titer
balf
improv
natur
killer
cell
activ
primari
phase
infect
day
infect
excess
immun
activ
cytokin
storm
oxid
stress
major
caus
mortal
iavinfect
mice
imbal
inflamm
antiinflamm
increas
pathogen
influenza
viru
compon
ggd
immunomodulatori
antiinflammatori
activ
thu
studi
investig
antiinflammatori
effect
ggd
iavinfect
mice
examin
antivir
mechan
ggd
measur
direct
antiiav
activ
ggd
vitro
vivo
determin
ggd
modul
host
immun
system
iavinfect
mice
reliev
inflamm
refer
substanc
gallic
acid
lot
oseltamivir
phosphat
purchas
medchemexpress
llc
nj
usa
herbal
materi
ggd
purchas
affili
hospit
shandong
univers
tradit
chines
medicin
jinan
shandong
china
authent
professor
xu
lingchuan
shandong
tradit
chines
medicin
univers
jinan
china
qualiti
herb
reach
standard
chines
pharmacopoeia
voucher
specimen
herbal
materi
kept
collabor
innov
center
accord
method
chines
pharmacopoeia
pueraria
lobat
wild
g
ephedra
sinica
g
cinnamomum
cassia
g
paeonia
lactiflora
g
glycyrrhiza
uralensi
g
zingib
officinal
g
ziziphu
jujuba
g
decoct
separ
ml
ml
water
minut
time
decoct
concentr
freezedri
obtain
lyophil
extract
powder
yield
stock
solut
refer
substanc
prepar
dissolv
powder
methanol
stock
solut
store
standard
work
solut
obtain
mix
dilut
stock
solut
lyophil
extract
powder
equival
g
raw
materi
dissolv
ml
methanol
solut
centrifug
min
supernat
filter
membran
lc
lcm
analysi
hplcqtofmsm
analysi
perform
agil
accuratemass
qtof
lcm
agil
technolog
santa
clara
ca
usa
equip
electrospray
ioniz
sourc
chromatograph
separ
carri
zorbax
sbc
column
mm
mm
agil
technolog
column
temperatur
set
mobil
phase
compos
formic
acidwat
b
acetonitril
gradient
elut
perform
follow
min
b
min
b
min
b
min
b
min
b
min
b
sampl
inject
volum
flow
rate
dad
detector
scan
nm
sampl
detect
nm
ms
detect
oper
paramet
neg
posit
ion
mode
set
follow
dri
ga
n
flow
rate
dri
ga
temperatur
capillari
voltag
v
nebul
pressur
psi
collis
energi
automat
optim
accord
ion
type
ms
rang
set
mz
agil
hplcdad
instrument
agil
technolog
ca
usa
use
hplc
determin
chromatograph
separ
condit
lc
ms
mention
madindarbi
canin
kidney
mdck
cell
acquir
cell
resourc
center
shanghai
academi
life
scienc
chines
academi
scienc
shanghai
china
cultur
dmem
gibco
ca
usa
contain
fb
gibco
ca
usa
penicillin
streptomycin
gibco
ca
usa
infect
carri
optimem
contain
tpcktrypsin
sigmaaldrich
mo
usa
mouseadapt
influenza
viru
iav
acquir
chines
center
diseas
control
prevent
beij
china
multipli
embryon
egg
tissu
cultur
infect
dose
tcid
viru
mdck
cell
lethal
dose
ld
viru
mice
determin
method
reedmuench
tcid
ml
ld
ml
variou
concentr
ggd
extract
oseltamivir
phosphat
op
inocul
mdck
cell
h
cytotox
concentr
cc
mdck
cell
determin
use
assay
kit
maximum
drug
concentr
caus
cell
mortal
rate
lower
chosen
drug
noncytotox
concentr
op
use
refer
control
briefli
cell
well
plate
plate
incub
h
cell
supplement
variou
concentr
ggd
op
immedi
viru
inocul
triplic
h
viru
inhibit
rate
determin
use
assay
calcul
equat
inhibitori
concentr
ic
valu
ggd
op
calcul
accord
reedmuench
method
test
model
control
model
timeofaddit
assay
antivir
activ
ggd
extract
examin
viral
inocul
briefli
mdck
cell
grown
plate
inocul
tcid
well
viru
variou
concentr
ggd
extract
supplement
h
h
h
h
viral
inocul
h
h
h
h
viral
inocul
h
incub
viru
inhibit
rate
determin
describ
effect
ggd
extract
viral
attach
intern
also
examin
describ
previous
briefli
attach
assay
cell
prechil
h
inocul
mixtur
viru
tcid
well
differ
concentr
ggd
extract
h
cell
monolay
firstli
wash
pb
buffer
cover
fresh
medium
incub
anoth
h
intern
assay
cell
prechil
h
inocul
viru
tcid
well
incub
h
medium
replac
fresh
medium
contain
variou
concentr
ggd
extract
cell
shift
cultur
h
cell
monolay
wash
pb
cover
medium
incub
anoth
h
effect
ggd
later
stage
viral
biosynthesi
singl
infecti
cycl
evalu
qrtpcr
briefli
cell
cellswel
grown
well
plate
inocul
viru
moi
incub
h
medium
replac
fresh
medium
contain
ggd
op
three
time
h
postinfect
viral
rna
supernat
isol
use
simpli
p
viru
rna
extract
kit
bio
flux
china
biorad
cfx
connect
apparatu
primer
mprotein
forward
primer
mprotein
revers
primer
recombin
plasmid
includ
mprotein
gene
influenza
viru
select
refer
substanc
experi
standard
curv
r
within
rang
copi
drawn
convert
c
number
viralgenom
copi
reaction
condit
follow
follow
cycl
denatur
anneal
extens
base
previou
report
femal
icr
mice
g
inocul
intranas
viral
suspens
ld
ld
pb
n
anesthesia
daili
dosag
ggd
extract
op
base
humanmous
equival
dosag
convers
mice
administ
ggd
op
distil
water
oral
day
day
infect
mortal
weight
clinic
featur
monitor
daili
next
two
week
mice
weight
loss
consid
dead
anoth
group
mice
inocul
ld
viru
day
infect
mice
administ
ggd
op
distil
water
oral
mice
euthan
prescrib
time
lung
peripher
blood
harvest
analysi
base
previou
report
viral
load
lung
tissu
determin
rtpcr
assay
anim
experi
process
line
approv
regul
anim
protect
use
committe
shandong
tradit
chines
medicin
univers
approv
octob
anim
maintain
laboratori
effort
made
minim
anim
suffer
number
anim
use
experi
lung
index
assess
pulmonari
edema
patholog
chang
observ
routin
paraffin
section
stain
hematoxylin
total
rna
lung
tissu
isol
use
rnaiso
plu
reagent
takara
bio
china
cdna
sampl
prepar
use
primescript
rt
reagent
kit
takara
bio
china
rtpcr
perform
sybr
premix
ex
tap
tm
ii
takara
bio
china
biorad
cfx
connect
apparatu
primer
describ
tabl
reaction
condit
follow
follow
cycl
denatur
anneal
extens
c
valu
analyz
use
compar
c
method
result
normal
gapdh
protein
extract
lung
tissu
ripa
buffer
beyotim
shanghai
china
contain
pmsf
beyotim
shanghai
china
phosphatas
inhibitor
cocktail
beyotim
shanghai
china
bca
protein
concentr
assay
kit
servicebio
technolog
co
ltd
wuhan
china
use
measur
protein
concentr
protein
separ
virusnp
sdspage
protein
transfer
pvdf
membran
millipor
darmstadt
germani
membran
separ
incub
variou
primari
antibodi
proteintech
group
illinoi
usa
affin
bioscienc
ohio
usa
virusnp
abcam
shanghai
china
affin
bioscienc
ohio
usa
abcam
shanghai
china
overnight
secondari
antibodi
incub
membran
min
protein
band
detect
ecl
kit
wuhan
servicebio
technolog
co
ltd
wuhan
china
visual
alpha
innotech
imag
system
san
leandro
ca
usa
differ
protein
blot
need
detect
second
set
specif
probe
primari
secondari
antibodi
clean
antibodi
strip
buffer
beyotim
jiangsu
china
detect
result
normal
result
express
mean
standard
deviat
sd
statist
analys
perform
use
twotail
independentsampl
test
wilcoxon
mannwhitney
test
conduct
statist
analysi
mortal
data
analyz
ibm
armonk
ny
usa
analyz
retent
time
molecular
ion
fragment
ion
chromatograph
peak
compar
result
refer
substanc
previou
literatur
data
compound
identifi
ggd
tabl
fig
includ
nineteen
flavonoid
three
organ
acid
three
monoterpenoid
two
triterpenoid
saponin
two
alkaloid
two
type
compound
content
seven
compon
antivir
antimicrobi
antiinflammatori
activ
ggd
determin
highperform
liquid
chromatographi
hplc
gallic
acid
puerarin
paeoniflorin
daidzin
daidzein
cinnam
acid
glycyrrhiz
acid
fig
vitro
experi
show
ggd
oseltamivir
phosphat
op
dosedepend
effect
mdck
cell
fig
calcul
ic
valu
ggd
op
respect
cc
ggd
wherea
op
preliminari
timeofaddit
assay
explor
possibl
antivir
mechan
ggd
drug
ad
differ
time
point
viral
inocul
activ
ggd
mdck
cell
dosedepend
timedepend
fig
ggd
effect
given
viral
infect
ic
valu
h
h
h
notic
differ
observ
h
infect
h
infect
suggest
ggd
might
interfer
attach
intern
viru
subsequ
attach
assay
confirm
hypothesi
ggd
inhibit
viral
attach
dosedepend
manner
fig
ic
howev
ggd
affect
viral
intern
fig
viral
genom
copi
supernat
analyz
quantit
rtpcr
qrtpcr
determin
whether
ggd
affect
later
stage
viral
biosynthesi
h
postinfect
number
viral
genom
copi
ggd
treatment
group
lower
model
group
fig
summari
ggd
show
antiiav
activ
vitro
ic
target
viral
attach
replic
stage
rather
intern
stage
next
investig
effect
ggd
iavinfect
mice
model
group
began
lose
bodi
weight
becam
inact
show
respiratori
distress
day
postinfect
ld
peak
number
death
appear
day
postinfect
although
similar
clinic
featur
ggd
group
less
sever
model
group
compar
model
group
mortal
significantli
reduc
ggd
treatment
adult
equival
dose
wherea
none
die
op
group
adult
equival
dose
fig
anoth
group
mice
inocul
subleth
dose
ld
bodi
weight
model
group
decreas
markedli
primari
phase
infect
gradual
recov
later
phase
fig
compar
model
group
bodi
weight
reduct
inhibit
ggd
op
treatment
summari
ggd
reduc
mortal
mice
infect
lethal
dose
viru
decreas
bodi
weight
loss
mice
infect
subleth
dose
viru
although
protect
effect
ggd
lower
op
lethal
dose
ld
cur
effect
ggd
compar
op
subleth
dose
ld
result
suggest
infect
dosag
ld
would
affect
therapeut
efficaci
ggd
reason
might
caus
discrep
surround
antiiav
effect
ggd
measur
rel
express
lung
tissu
virusinfect
mice
ld
rtpcr
assay
show
viru
titer
lung
tissu
model
group
peak
day
postinfect
fell
day
postinfect
p
fig
viru
titer
lung
tissu
ggd
op
group
significantli
reduc
p
day
postinfect
viru
titer
ggd
group
higher
op
group
p
howev
signific
differ
viru
titer
ggd
group
op
group
day
postinfect
p
express
viral
nucleoprotein
lung
tissu
day
postinfect
also
confirm
result
fig
result
indic
influenza
resolv
mice
infect
subleth
dose
ld
howev
lung
index
fig
patholog
chang
fig
model
group
show
immun
system
would
inevit
caus
inflammatori
injuri
process
remov
viru
consist
clinic
observ
treatment
ggd
op
reliev
lung
injuri
compar
model
group
ggd
op
treatment
improv
lung
index
fig
histolog
chang
fig
day
postinfect
summari
ggd
direct
antiiav
activ
vitro
vivo
ggd
treatment
significantli
reduc
viru
titer
lung
tissu
allevi
patholog
damag
mice
infect
ld
compon
ggd
immunomodulatori
antiinflammatori
activ
thu
studi
requir
verifi
antiinflammatori
immunomodulatori
hypothesi
ggd
treatment
influenza
express
cytokin
lung
tissu
measur
rtpcr
western
blot
day
postinfect
rtpcr
assay
show
mrna
express
model
group
significantli
higher
control
group
compar
model
group
express
mrna
reduc
ggd
op
treatment
consist
previou
research
fig
rtpcr
assay
indic
mrna
express
model
group
significantli
higher
control
group
mrna
express
ggd
op
group
lower
model
group
fig
notabl
express
mrna
ggd
group
lower
op
group
p
fig
protein
express
consist
mrna
data
fig
import
proinflammatori
cytokin
caus
sever
damag
lung
influenza
infect
overexpress
proinflammatori
cytokin
increas
pathogen
influenza
viru
compar
model
group
express
lung
tissu
decreas
significantli
treatment
ggd
op
howev
compar
op
group
ggd
group
exhibit
uniqu
immunomodulatori
effect
level
lung
tissu
treatment
ggd
lower
op
group
main
cytokin
caus
acut
lung
injuri
propos
decreas
express
ggd
group
help
reliev
inflammatori
injuri
iavinfect
mice
eii
differ
lung
tissu
model
group
narrow
alveolar
space
black
arrow
thicken
alveolar
wall
lung
congest
red
arrow
infiltr
inflammatori
cell
green
arrow
degre
lung
lesion
reduc
greatli
treat
group
alveolar
morpholog
follow
ggd
eiii
op
eiv
treatment
normal
data
present
mean
sd
p
p
vs
model
group
p
p
vs
control
group
explor
whether
ggd
exert
antiinflammatori
effect
regul
immun
balanc
measur
express
cytokin
respect
lung
tissu
rtpcr
western
blot
compar
control
group
express
increas
wherea
express
decreas
model
group
day
postinfect
howev
compar
model
group
express
decreas
fig
wherea
express
increas
fig
treatment
ggd
op
compar
op
group
level
ggd
group
closer
control
group
result
indic
ggd
regul
host
immun
system
maintain
balanc
determin
effect
ggd
balanc
percentag
cell
peripher
lymphocyt
determin
flow
cytometri
compar
control
group
ratio
model
group
significantli
increas
p
suggest
balanc
push
toward
infect
fig
interestingli
compar
op
group
ratio
ggd
group
closer
control
group
result
suggest
antiinflammatori
effect
ggd
may
relat
improv
immun
balanc
data
present
mean
sd
p
p
vs
model
group
p
p
vs
control
group
mous
th
cell
divid
subgroup
differ
function
accord
type
cytokin
secret
healthi
individu
cell
ratio
maintain
dynam
balanc
imbal
relat
induct
inflamm
occurr
variou
immun
diseas
studi
show
cell
ratio
skew
toward
infect
although
cellmedi
antiinfect
immun
respons
essenti
clearanc
influenza
viru
cytokin
also
mediat
inflammatori
damag
earli
stage
influenza
pair
mutual
inhibitori
cytokin
indirectli
reflect
degre
immun
respons
immunomodul
function
ggd
infer
compar
chang
express
ggd
op
group
compar
op
group
level
lung
tissu
ratio
peripher
lymphocyt
ggd
group
closer
control
group
thu
believ
ggd
regul
immun
system
maintain
balanc
avoid
overactiv
inflamm
tolllik
receptor
protein
recogn
influenza
viru
trigger
immun
respons
thu
examin
effect
ggd
signal
pathway
measur
mrna
protein
express
key
protein
signal
pathway
rtpcr
assay
show
express
myeloid
differenti
primari
respons
tnf
receptor
associ
factor
interferon
regulatori
factor
mrna
model
group
significantli
higher
control
group
day
postinfect
fig
compar
model
group
mrna
express
decreas
ggd
op
treatment
howev
express
nuclear
factor
nf
mrna
similar
ggd
op
group
similar
mrna
level
express
phospho
p
protein
model
group
increas
ratio
increas
express
protein
decreas
fig
although
notic
differ
mrna
express
among
group
reduc
express
protein
indic
trigger
degrad
indic
activ
pathway
compar
model
group
express
protein
ggd
op
group
reduc
ratio
decreas
express
protein
recov
moreov
ratio
ggd
group
lower
op
group
p
howev
express
total
protein
similar
ggd
op
group
suggest
chang
express
protein
result
chang
total
protein
data
present
mean
sd
p
p
vs
model
group
p
p
vs
control
group
tolllik
receptor
pattern
recognit
receptor
play
essenti
role
recogn
pathogen
induc
cascad
signal
immun
respons
recogn
singlestrand
rna
influenza
virus
trigger
immun
respons
seri
cascad
reaction
antivir
pathway
mediat
signal
pathway
may
howev
signal
pathway
also
play
essenti
role
develop
acut
lung
injuri
induc
influenza
viru
appropri
activ
signal
pathway
necessari
combat
infect
howev
pathway
properli
control
continu
bulk
releas
inflammatori
cytokin
caus
inflammatori
injuri
present
studi
express
activ
level
lung
tissu
increas
significantli
postinfect
ggd
treatment
mrna
protein
express
decreas
activ
level
decreas
consist
allevi
patholog
damag
addit
activ
ggd
treatment
lower
op
group
result
requir
explan
summari
focus
antiinflammatori
immunomodulatori
activ
ggd
compar
sever
immunerel
index
ggd
op
group
found
ggd
treatment
decreas
express
reliev
lung
injuri
ggd
treatment
also
regul
balanc
allevi
inflamm
addit
ggd
treatment
decreas
level
activ
although
reason
remain
unclear
ggd
use
clinic
practic
year
howev
know
littl
pharmacolog
mechan
treat
influenza
infect
demonstr
ggd
possess
antiiav
activ
vitro
vivo
addit
ggd
downregul
express
proinflammatori
cytokin
regul
immun
balanc
reduc
inflamm
improv
prognosi
mice
infect
signal
pathway
also
involv
immunoregul
ggd
treatment
result
indic
ggd
may
use
antiiav
medicin
owe
uniqu
antiinflammatori
immunomodulatori
activ
